Jump to content

Talk:Grail (company)

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

COI edit requests

[edit]

Hi! I'm a COI editor posting on behalf of GRAIL, a client of my employer, Porter Novelli. Requesting some updates to this article below. I've also mocked up all the edits here if helpful. There are several items in this request; please let me know if it would be preferable to share in batches rather than all at once and I can do so.

  • Throughout the article: lots of single quotes around phrases that don't seem to need them, e.g. 'Galleri test'. Could these be deleted? Happy to do so myself if helpful.
  • The company was actually established in 2016, not 2015.[1] This needs to be updated in a few places in the article, as well as some categories.
  • The term "liquid biopsy" is used a few times in the article. This may be misleading because Galleri is a screening tool, not a diagnostic; additional follow-up testing is required to confirm the presence of cancer.[2][3] "Multi-cancer early detection test" would be more accurate.
  • It looks like the consensus is to hyphenate "multi-cancer". Currently, it appears as one word in a few places in this article.
  • Per {{Use mdy dates}} at the top of the article, converting a few dates throughout the article: 27 November 2020, 31 August 2021, 15 July 2024 and 28 February 2026.

Origin

[edit]
  • I think it makes sense to update this section title to "History" or "Background" since it covers more than just the company's origin.
  • Delete "Grail's chairman is Jay Flatley."; this is no longer true.[4]
  • Add before "According to Forbes in 2017,":
Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, championed the new business[5] and joined its board of directors.[6]

Galleri test

[edit]
  • Perhaps this could be broken into "Technology" (currently the first paragraph, explaining how the test works) and "Research" sections (the remaining content, on the studies done on the test).
  • Update "providing information of the origin" to "predicting the origin" for clarity.
  • Add after "The Galleri test detects fragments of DNA in a blood sample via next-generation sequencing, which identifies DNA methylation, distinct patterns of which are associated with particular cancers, potentially allowing early detection of cancer and providing information of the origin of the cancer.":
Galleri received breakthrough device designation from the U.S. Food and Drug Administration in May 2019.[8] The test does not diagnose cancer; rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing.[7] Galleri is not yet approved by the FDA, but it is available by prescription under the agency's provision for laboratory developed tests.[9][10]
  • Add after "Subsequently the Galleri test entered into a further three trials; STRIVE, SUMMIT, and PATHFINDER studies.":
Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer.[11] The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy.[12] Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.[13]
  • Add after "The trial started on 31 August 2021, with primary completion date estimated at 15 July 2024 and study completion on 28 February 2026.[14]":
In a separate NHS trial in collaboration with Oxford University, the SYMPLIFY study is evaluating the test's utility for symptomatic individuals.[15] Initial results shared in June 2023 showed that the test correctly detected two out of three cancers among 5,000 individuals who presented with symptoms. The test also accurately predicted the cancer signal origin in 85% of those cases.[16]
  • Add before "As of January 2023..."
In May 2021, Grail announced that Providence Health & Services would be the first health system in the U.S. to offer access to the Galleri test.[17] The next month, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test.[18] Point32Health, parent of Tufts Health Plan and Harvard Pilgrim Health Care, became the first commercial insurance provider to offer the test in November 2022.[19]
  • Add to end of last paragraph:
Grail stated that more than half of the people who received erroneous letters had not yet had their blood drawn for the test.[20]


Sources

  1. ^ Terry, Mark (9 January 2017). "What You Need to Know About GRAIL". BioSpace. Retrieved 26 June 2023.
  2. ^ "The Galleri Blood Test: What To Know". Health. 21 December 2022. Retrieved 11 July 2023.
  3. ^ "Galleri cancer test: What is it and who can get it?". BBC News. 13 September 2021. Retrieved 11 July 2023.
  4. ^ "Who We Are". GRAIL. Retrieved 26 June 2023.
  5. ^ Leuty, Ron (27 May 2021). "Biotech's elder statesman is still going strong". San Francisco Business Times. Retrieved 25 June 2023.
  6. ^ "Illumina Launches GRAIL, Focused on Blood-Based Cancer Screening". GEN - Genetic Engineering and Biotechnology News. 11 January 2016. Retrieved 25 June 2023.
  7. ^ a b Bohannan, Larry (23 March 2023). "PGA Tour Champions tourney spreads word on Galleri early cancer detection test". The Desert Sun. Retrieved 25 June 2023.
  8. ^ Tirumalaraju, Divya (14 May 2019). "Grail gets FDA breakthrough designation for multi-cancer test". Medical Device Network. Retrieved 26 June 2023.
  9. ^ Kolata, Gina (10 June 2022). "Blood Tests That Detect Cancers Create Risks for Those Who Use Them". The New York Times. Retrieved 25 June 2023.
  10. ^ Hale, Conor (7 June 2021). "Grail launches long-awaited Galleri blood test, its groundbreaking multi-cancer screening diagnostic". Fierce Biotech. Retrieved 26 June 2023.
  11. ^ Longworth, Catherine (22 September 2022). "ESMO shines a light on early cancer detection difficulties". Medical Device Network. Retrieved 25 June 2023.
  12. ^ Sidharthan, Chinta (13 September 2022). "Final results of the PATHFINDER study by GRAIL on multi-cancer early detection tests announced". News-Medical.net. Retrieved 25 June 2023.
  13. ^ Barndollar, Hadley (27 October 2022). "Multi-cancer early detection tests could save lives, but we still have a lot to learn". The Providence Journal. Retrieved 25 June 2023.
  14. ^ "Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial". ClinicalTrials.gov. 10 November 2022. NCT05611632.
  15. ^ "Multi-cancer blood test shows real promise in NHS trial". University of Oxford. 2 June 2023. Retrieved 25 June 2023.
  16. ^ Roberts, Michelle (1 June 2023). "Multi-cancer blood test shows real promise in NHS study". BBC News. Retrieved 25 June 2023.
  17. ^ Nelson, Roxanne (17 May 2021). "Blood Test for 50 Cancers Coming to US Clinics Soon". Medscape. Retrieved 25 June 2023.
  18. ^ Nathan-Kazis, Josh (4 June 2021). "Grail Will Begin Selling Its Multi-Cancer Blood Test". Barron's. Retrieved 25 June 2023.
  19. ^ Johnston, Katie (27 November 2022). "Point32Health evaluating blood test benefit to screen for 50 types of cancer - The Boston Globe". The Boston Globe. Retrieved 25 June 2023.
  20. ^ Holpuch, Amanda (4 June 2023). "Hundreds Were Mistakenly Told They Might Have Cancer, Test Company Says". The New York Times. Retrieved 25 June 2023.

Thank you for your time and consideration! Mary Gaulke (talk) 22:46, 13 July 2023 (UTC)[reply]

Reply 15-JUL-2023

[edit]

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  14:04, 15 July 2023 (UTC)[reply]

Edit request review 15-JUL-2023

The company was established in 2016.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


The term "multi-cancer early detection test" would be more accurate.
no Declined.[note 1]


Converting a few dates throughout the article
 Not an actionable request.[note 2]


Delete chairman Joe Flatley.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Klausner, then chief medical officer at Illumina, championed the new business and joined its board of directors.
Clarification needed.[note 3]


The company sponsored the Galleri Classic golf tournament
 Unable to implement.[note 4]


Update "providing information of the origin" to "predicting the origin"
no Declined.[note 5]


Galleri received breakthrough device designation from the US FDA in May 2019.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


The test does not diagnose cancer; rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing.
no Declined.[note 6]


Galleri is available by prescription under the FDA's provision for laboratory developed tests.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Results from Pathfinder presented in Sept 2022 showed a 43.1% positive predictive value for the detection of early stage cancer. The study found that the number of cancer detections doubled ... the test also predicted the cancer signal origin with 97% accuracy ... (text continues) ... of the more than 6,000 participants ... (text continues) ... for which no routine screening is available.
no Declined.[note 7]


In a seperate NHS trial in collaboration with ... (text continues) ... for symptomatic individuals.
no Declined.[note 8]


Initial results shared in June 2023 ...
no Declined.[note 9]


In May 2021, Grail announced that Providence Health and Services would be the first health system to offer the Galleri system. The next month, the company began selling Galleri tests in the US....
no Declined.[note 10]


Grail stated that more than half of the people who received erroneous letters had not yet had their blood drawn for the test.
 Unable to review.[note 11]


___________

  1. ^ The term "screening tool" was used to describe this item, whereas it was suggested that the phrase "cancer detection test" be used. No references were provided stating that this terminology is best to use.
  2. ^ Minor changes to Wiki-markup, including date formatting, falls under the rubric of uncontroversial edits, which are not covered by the COI edit request review process. (See WP:COIU.)
  3. ^ It isn't clear what is meant by the term "championed".
  4. ^ The Wikilink for "Galleri Classic golf tournament" was not included with the requested text.
  5. ^ References have not been provided which unequivocally state that the item predicts rather than provides information on the origin.
  6. ^ The Desert Sun reference provided with this claim is general news media. (See WP:MEDPOP.)
  7. ^ The reference provided with this claim is not the same authoritative source used to officially communicate Pathfinder results. (See WP:SWYGT.)
  8. ^ This information refers to an ongoing or otherwise unconcluded trial.
  9. ^ The phrase "initial results" suggests that the trial is not concluded or that the findings are preliminary.
  10. ^ Information regarding with whom the company chose to manage/oversee/handle the release of the company's medical merchandise is promotional in nature.
  11. ^ Additional context and/or reasons for including this text have not been provided. Thus, the statement cannot be fully evaluated for its appropriateness.

Revised edit request

[edit]

@Spintendo: Hello! Thanks for your review.

  • Note 1: Some references for the term "multi-cancer early detection test": [1][2][3]
  • Note 3: Revised:

Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business[4] and joined its board of directors.[5]

  • Note 5: Some references using the term "predict" for cancer signal origin: [3][6][7]
  • Note 6: Updated refs:

The test does not diagnose cancer;[3] rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing.[8]

  • Note 7: Added primary source refs:

Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer.[9][10][11] The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy.[12] Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.[13]

  • Note 10: Understood on the partnerships, but I do want to check if this is notable:

In June 2021, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test.[14] Thanks again! Mary Gaulke (talk) 15:41, 26 July 2023 (UTC)[reply]

 Reviewing soon Thank you for your reply. I'll review this shortly. Regards,  Spintendo  19:18, 17 August 2023 (UTC)[reply]
With regards to Note 1, please specify which of these three references to use. Note 3 has changed "championed" to "advocated" but the underlying question still remains what is meant by this. Note 5, there are 3 references, but it's unclear which of these three to use for the proposed statement. Note 6 was implemented (the Health.com source is not the best I would have hoped for, but it appears to have been "reviewed" by an MD, whatever that means). Note 7 contains a statement which has three references. If all three of these references confirm the information, then only one of them should be supplied (they are all correctly from ESMO, so any one fo them should suffice.) The information following that first sentence can only be implemented after the first sentence's references are settled (so that it reads correctly) Regards,  Spintendo  17:33, 21 August 2023 (UTC)[reply]
@Spintendo: Thanks for the review! For what it's worth, I've been advised in the past to provide multiple sources in order to demonstrate the notability of a piece of information and/or to show media consensus around certain terminology. Sounds like I should adjust my best practices.
Note 1: Use [15]
Note 3: Does this suit better? (Trying not to stray too far from the source material.)
Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business, correctly predicting how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample.[16] He also joined Grail's board of directors.[17]
Note 5: Use [18][19]
Note 7: Revised:
Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer.[20] The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy.[21] Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.[22]
And following up on Note 10 just in case it was missed, checking if this is notable:
In June 2021, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test.[23]
Thanks again! Mary Gaulke (talk) 21:38, 21 August 2023 (UTC)[reply]
Thank you for your reply.
  1. Providing multiple sources is good for establishing notability, but it's not necessary for an article's content. For example, if a claim is made in the New York Times, there does not need to be additional sources from industry-related journals and blogs.
  2. "and/or to show media consensus around certain terminology" this is also absolutely correct. However, when you say media, what that should mean is reliable, independent, journalistic secondary sources. This ought not to include media covering the industry in question, as these types of media often are providing company-originating information, i.e., press releases and company statements (such as an interview with a company spokesperson/executive which are published verbatim and without any further verification). Those type of statements are easily seen within these sources reading as "According to....." or "...the company said last Friday." etc. In those instances, the devil is in the details, so to speak.
  3. Now the sources you're mentioning above, are these "requested to be added" or "requested to be used" or are they to be deleted? If they are to be added, I would ask in these sources (like the SF Business Times, Genetic Engineering and Biotechnology News, Medical Device Network, and News-Medical.net) are there any instances where the example phrases I've mentioned above are being used in those articles? If they are, even once, then that would be a big clue that these are sources to be avoided. Regards,  Spintendo  18:54, 1 September 2023 (UTC)[reply]
@Spintendo: Thanks for the reply!
1. Understood!
2. This also makes sense. That said, I do think consensus across ACS,[24] a medical journal,[25] and a consumer health site[3] indicates that the term "multi-cancer early detection test" is in widespread use, both in reference to Galleri and more generally.
3. I believe my use of the above sources is completely appropriate. Several cite peer reviewed medical studies, and while a few reference the existence of GRAIL statements, they're not connected to the information I'm referencing (e.g. while GEN quotes a GRAIL exec, the information being cited isn't related to the quote; the source is being used to confirm Klausner's appointment to GRAIL's board).
Happy to re-compile and post the latest revisions to the requests if helpful. Just let me know. Thank you! Mary Gaulke (talk) 18:54, 12 September 2023 (UTC)[reply]

References

  1. ^ "Multi-cancer Early Detection Tests – MCED – GRAIL Galleri Test". American Cancer Society. Retrieved 26 July 2023.
  2. ^ Pyzocha, Natasha J. (October 2022). "Galleri Test for the Detection of Cancer". American Family Physician. 106 (4): 459–460. ISSN 1532-0650.
  3. ^ a b c d "The Galleri Blood Test: What To Know". Health. 21 December 2022. Retrieved 26 July 2023.
  4. ^ Leuty, Ron (27 May 2021). "Biotech's elder statesman is still going strong". San Francisco Business Times. Retrieved 25 June 2023.
  5. ^ "Illumina Launches GRAIL, Focused on Blood-Based Cancer Screening". GEN - Genetic Engineering and Biotechnology News. 11 January 2016. Retrieved 25 June 2023.
  6. ^ Nicholson, Brian D; Oke, Jason; Virdee, Pradeep S; Harris, Dean A; O'Doherty, Catherine; Park, John ES; Hamady, Zaed; Sehgal, Vinay; Millar, Andrew; Medley, Louise; Tonner, Sharon; Vargova, Monika; Engonidou, Lazarina; Riahi, Kaveh; Luan, Ying; Hiom, Sara; Kumar, Harpal; Nandani, Harit; Kurtzman, Kathryn N; Yu, Ly-Mee; Freestone, Clare; Pearson, Sarah; Hobbs, FD Richard; Perera, Rafael; Middleton, Mark R (July 2023). "Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study". The Lancet Oncology. 24 (7): 733–743. doi:10.1016/S1470-2045(23)00277-2.
  7. ^ Sasieni, Peter; Smittenaar, Rebecca; Hubbell, Earl; Broggio, John; Neal, Richard D.; Swanton, Charles (July 2023). "Modelled mortality benefits of multi-cancer early detection screening in England". British Journal of Cancer. 129 (1): 72–80. doi:10.1038/s41416-023-02243-9. ISSN 1532-1827.
  8. ^ Sample, Ian (11 September 2022). "Blood test spots multiple cancers without clear symptoms, study finds". The Guardian. Retrieved 26 July 2023.
  9. ^ "903O - A prospective study of a multi-cancer early detection blood test". ESMO Congress – OncologyPRO. 11 September 2022. Retrieved 26 July 2023.
  10. ^ "A New Era of Early Cancer Detection With Blood Test May Change Cancer Screening Paradigms [ESMO Congress 2022 Press Release]". ESMO. 11 September 2022. Retrieved 26 July 2023.
  11. ^ Longworth, Catherine (22 September 2022). "ESMO shines a light on early cancer detection difficulties". Medical Device Network. Retrieved 25 June 2023.
  12. ^ Sidharthan, Chinta (13 September 2022). "Final results of the PATHFINDER study by GRAIL on multi-cancer early detection tests announced". News-Medical.net. Retrieved 25 June 2023.
  13. ^ Barndollar, Hadley (27 October 2022). "Multi-cancer early detection tests could save lives, but we still have a lot to learn". The Providence Journal. Retrieved 25 June 2023.
  14. ^ Nathan-Kazis, Josh (4 June 2021). "Grail Will Begin Selling Its Multi-Cancer Blood Test". Barron's. Retrieved 25 June 2023.
  15. ^ Pyzocha, Natasha J. (October 2022). "Galleri Test for the Detection of Cancer". American Family Physician. 106 (4): 459–460. ISSN 1532-0650.
  16. ^ Leuty, Ron (27 May 2021). "Biotech's elder statesman is still going strong". San Francisco Business Times. Retrieved 25 June 2023.
  17. ^ "Illumina Launches GRAIL, Focused on Blood-Based Cancer Screening". GEN - Genetic Engineering and Biotechnology News. 11 January 2016. Retrieved 25 June 2023.
  18. ^ Nicholson, Brian D; Oke, Jason; Virdee, Pradeep S; Harris, Dean A; O'Doherty, Catherine; Park, John ES; Hamady, Zaed; Sehgal, Vinay; Millar, Andrew; Medley, Louise; Tonner, Sharon; Vargova, Monika; Engonidou, Lazarina; Riahi, Kaveh; Luan, Ying; Hiom, Sara; Kumar, Harpal; Nandani, Harit; Kurtzman, Kathryn N; Yu, Ly-Mee; Freestone, Clare; Pearson, Sarah; Hobbs, FD Richard; Perera, Rafael; Middleton, Mark R (July 2023). "Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study". The Lancet Oncology. 24 (7): 733–743. doi:10.1016/S1470-2045(23)00277-2.
  19. ^ Sasieni, Peter; Smittenaar, Rebecca; Hubbell, Earl; Broggio, John; Neal, Richard D.; Swanton, Charles (July 2023). "Modelled mortality benefits of multi-cancer early detection screening in England". British Journal of Cancer. 129 (1): 72–80. doi:10.1038/s41416-023-02243-9. ISSN 1532-1827.
  20. ^ Longworth, Catherine (22 September 2022). "ESMO shines a light on early cancer detection difficulties". Medical Device Network. Retrieved 25 June 2023.
  21. ^ Sidharthan, Chinta (13 September 2022). "Final results of the PATHFINDER study by GRAIL on multi-cancer early detection tests announced". News-Medical.net. Retrieved 25 June 2023.
  22. ^ Barndollar, Hadley (27 October 2022). "Multi-cancer early detection tests could save lives, but we still have a lot to learn". The Providence Journal. Retrieved 25 June 2023.
  23. ^ Nathan-Kazis, Josh (4 June 2021). "Grail Will Begin Selling Its Multi-Cancer Blood Test". Barron's. Retrieved 25 June 2023.
  24. ^ "Multi-cancer Early Detection Tests – MCED – GRAIL Galleri Test". American Cancer Society. Retrieved 26 July 2023.
  25. ^ Pyzocha, Natasha J. (October 2022). "Galleri Test for the Detection of Cancer". American Family Physician. 106 (4): 459–460. ISSN 1532-0650.

Regarding "multicancer early detection (MCED) test" I see that this is the term already in use in the article, so I'm not understanding what it is you want changed about that. If you have a new request, please feel free to post it under a new level 2 heading at the bottom of the talk page. Regards,  Spintendo  20:28, 27 September 2023 (UTC)[reply]


Moved page

[edit]

The page had been at GRAIL (company), Per MOS:TMRULES, we're to use standard case even if the owner prefers ALL CAPS if standard case is commonly used by third parties, and in my quick check of key sources used here like Forbes, Wall Street Journal, Reuters, etc, all used Grail. -- Nat Gertler (talk) 06:57, 18 August 2023 (UTC)[reply]

Revised edit requests October 2023

[edit]

Hello! Updating the above edit requests to reflect all feedback.

  • Delete unnecessary single quotes around 'Galleri test' and other phrases throughout the article.
  • Update the phrase "liquid biopsy" to "multi-cancer early detection test", which is the primary descriptor used for the Galleri test and tests like it in the media.[1]
  • Update "multicancer" (which appears once in the lead and three times in the "Galleri test" section) to "multi-cancer", the standard spelling in most media.
  • Rename the "Origin" section to "History" since it covers more than the company's origin.
  • In the "Origin" section, add before "According to Forbes in 2017,":
Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business, correctly predicting how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample.[2] He also joined Grail's board of directors.[3]
  • In the "Galleri test" section, update "providing information of the origin" to "predicting the origin".[4][5] This phrase should also be updated in the lead.
  • Add after "Galleri received breakthrough device designation from the U.S. Food and Drug Administration in May 2019.[6]":
The test does not diagnose cancer;[7] rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing.[8]
  • Add after "Subsequently the Galleri test entered into a further three trials; STRIVE, SUMMIT, and PATHFINDER studies.":
Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer.[9] The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy.[10] Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.[11]
  • Add before "As of January 2023..."
In June 2021, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test.[12]
Sources

  1. ^ Pyzocha, Natasha J. (October 2022). "Galleri Test for the Detection of Cancer". American Family Physician. 106 (4): 459–460. ISSN 1532-0650.
  2. ^ Leuty, Ron (27 May 2021). "Biotech's elder statesman is still going strong". San Francisco Business Times. Retrieved 25 June 2023.
  3. ^ "Illumina Launches GRAIL, Focused on Blood-Based Cancer Screening". GEN - Genetic Engineering and Biotechnology News. 11 January 2016. Retrieved 25 June 2023.
  4. ^ Nicholson, Brian D; Oke, Jason; Virdee, Pradeep S; Harris, Dean A; O'Doherty, Catherine; Park, John ES; Hamady, Zaed; Sehgal, Vinay; Millar, Andrew; Medley, Louise; Tonner, Sharon; Vargova, Monika; Engonidou, Lazarina; Riahi, Kaveh; Luan, Ying; Hiom, Sara; Kumar, Harpal; Nandani, Harit; Kurtzman, Kathryn N; Yu, Ly-Mee; Freestone, Clare; Pearson, Sarah; Hobbs, FD Richard; Perera, Rafael; Middleton, Mark R (July 2023). "Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study". The Lancet Oncology. 24 (7): 735. doi:10.1016/S1470-2045(23)00277-2.
  5. ^ Sasieni, Peter; Smittenaar, Rebecca; Hubbell, Earl; Broggio, John; Neal, Richard D.; Swanton, Charles (July 2023). "Modelled mortality benefits of multi-cancer early detection screening in England". British Journal of Cancer. 129 (1): 72. doi:10.1038/s41416-023-02243-9. ISSN 1532-1827.
  6. ^ Tirumalaraju, Divya (14 May 2019). "Grail gets FDA breakthrough designation for multi-cancer test". Medical Device Network. Retrieved 26 June 2023.
  7. ^ "The Galleri Blood Test: What To Know". Health. 21 December 2022. Retrieved 26 July 2023.
  8. ^ Sample, Ian (11 September 2022). "Blood test spots multiple cancers without clear symptoms, study finds". The Guardian. Retrieved 26 July 2023.
  9. ^ "903O - A prospective study of a multi-cancer early detection blood test". ESMO Congress – OncologyPRO. 11 September 2022. Retrieved 26 July 2023.
  10. ^ Sidharthan, Chinta (13 September 2022). "Final results of the PATHFINDER study by GRAIL on multi-cancer early detection tests announced". News-Medical.net. Retrieved 25 June 2023.
  11. ^ Barndollar, Hadley (27 October 2022). "Multi-cancer early detection tests could save lives, but we still have a lot to learn". The Providence Journal. Retrieved 25 June 2023.
  12. ^ Nathan-Kazis, Josh (4 June 2021). "Grail Will Begin Selling Its Multi-Cancer Blood Test". Barron's. Retrieved 25 June 2023.

Thanks for your help! Mary Gaulke (talk) 12:10, 4 October 2023 (UTC)[reply]

@MaryGaulke Thank you for both reducing the number of excess references and for clarifying which changes are to be made. One final question, with regards to the Nicholson et.al and the Sasieni et.al sources, the first gives pages 733-743 and the second gives pages 72-80, are those the pages that the entire report exists on, or are those the pages were the actual information claimed in the proposed text exists? It seems like a lot of pages if it's the latter. Please advise. Thanks! Regards,  Spintendo  16:30, 4 October 2023 (UTC)[reply]
@Spintendo: Hello! Confirming it's the former – those are the pages on which the reports appear. Please let me know if I should revise somehow. Thanks! Mary Gaulke (talk) 16:52, 4 October 2023 (UTC)[reply]
@MaryGaulke:Thank you for the clarification. If you could revise the |pages= parameter of the citation so that it displays only the pages where the sourced information appears, that would be most helpful. Thank you! Regards,  Spintendo  19:23, 4 October 2023 (UTC)[reply]
@Spintendo: No problem. This is updated above! Mary Gaulke (talk) 20:12, 4 October 2023 (UTC)[reply]

Reply 7-OCT-2023

[edit]

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.

Edit request review 7-OCT-2023

Delete unnecessary single quotes around 'Galleri test' and other phrases throughout the article.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Update the phrase "liquid biopsy" to "multi-cancer early detection test", which is the primary descriptor used for the Galleri test and tests like it in the media.
 Approved.[note 1]


Update "multicancer" (which appears once in the lead and three times in the "Galleri test" section) to "multi-cancer", the standard spelling in most media.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Rename the "Origin" section to "History" since it covers more than the company's origin.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Dr. Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business, correctly predicting how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample. He also joined Grail's board of directors.
no Declined.[note 2]


In the "Galleri test" section, update "providing information of the origin" to "predicting the origin". This phrase should also be updated in the lead.
no Declined.[note 3]


The test does not diagnose cancer; rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer.
 Approved.Cite error: There are <ref> tags on this page without content in them (see the help page).


The study found that the number of cancer detections doubled when multicancer screening was included in the standard of care screening, compared to using only standard screening. The test also predicted the cancer signal origin with 97% accuracy. Of the more than 6,000 participants in PATHFINDER, 35 were diagnosed with cancer, and 71% of those diagnosed were diagnosed with cancer types for which no routine screening is available.
no Declined.[note 4]


In June 2021, the company began selling Galleri tests in the U.S., making it the first commercially available multi-cancer early detection test
 Partly-approved.[note 5]


___________

  1. ^ This additional information was placed in parenthesis. The term "liquid biopsy", because it is placed as a Wikilink, was retained so that readers may access that article.
  2. ^ The term "correctly predicting" is used by the San Francisco Business Times and thus, should have been indicated in the proposed text by stating "Richard Klausner, according to the San Francisco Business Times, correctly predicted how DNA sequencing technology...." Additionally, Klausner is labeled "Dr." in the proposed text, which is not an acceptable way to describe individuals with medical licenses in Wikipedia articles. (See MOS:DOCTOR.)
  3. ^ A reason was not provided for why the proposed description is superior to that already used in the article. If the reason was provided in an earlier edit request, that reason was not carried over to the current request.
  4. ^ The information presented in this portion of the edit request is not referenced by the study itself, rather, it is referenced by announcements of the results made in other media. If the claim is that the study itself is making these findings, then the study itself should be presented as the reference.
  5. ^ The claim of being first-to-market is promotional in nature and was not included in the text added to the article.

Regards,  Spintendo  22:49, 7 October 2023 (UTC)[reply]

Revised edit requests October 2023 v.2

[edit]

Hi again – following up on just a few items from above per the feedback received.

  • In the "History" section, add before "According to Forbes in 2017,":
Richard Klausner, then chief medical officer at Illumina and former director of the National Cancer Institute, advocated for the new business. According to the San Francisco Business Times, he correctly predicted how DNA sequencing technology would make it possible to detect evidence of a tumor from a blood sample.[1] He also joined Grail's board of directors.[2]
  • Add after "Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer.[3]":
Additionally, the test predicted the cancer signal origin with 97% accuracy.[3]

References

  1. ^ Leuty, Ron (27 May 2021). "Biotech's elder statesman is still going strong". San Francisco Business Times. Retrieved 25 June 2023.
  2. ^ "Illumina Launches GRAIL, Focused on Blood-Based Cancer Screening". GEN - Genetic Engineering and Biotechnology News. 11 January 2016. Retrieved 25 June 2023.
  3. ^ a b "903O - A prospective study of a multi-cancer early detection blood test". ESMO Congress – OncologyPRO. 11 September 2022. Retrieved 26 July 2023.

Thanks for your assistance. Mary Gaulke (talk) 15:15, 18 October 2023 (UTC)[reply]

Reply 18-OCT-2023

[edit]

✅  Edit request partially implemented  

  1. Green tickY The information concerning Klausner was added to the indicated section.
  2. Red XN The information concerning PATHFINDER was not added because clear directions for the text's emplacement were not given (e.g., Add after "Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer. "add after" does not state after what).

Regards,  Spintendo  21:39, 18 October 2023 (UTC)[reply]

@Spintendo: Hi! To be clear, on point 2 above, the text you quoted is the text after which the new text should be inserted. The new text (i.e. "Additionally, the test predicted the cancer signal origin with 97% accuracy.[1]") is on the following line. Thank you! Mary Gaulke (talk) 20:07, 23 October 2023 (UTC)[reply]
To be clear, the text you quoted is the text after which the new text should be inserted. I'm afraid it's not at all clear. Edit requests should ideally contain only what is being added or removed. Anything that "carries over" should not be here. If the text that I quoted is the text after which the new text is to be inserted, then why is this text (after which the new text is to be inserted) in your request? Needless to say, you and I could re-enact what appears to be our own version of Who's on First? all day long but it would really just be quicker to submit a new request. Thank you! Regards,  Spintendo  03:34, 3 November 2023 (UTC)[reply]

Edit request Nov 2023

[edit]

Hi! Just a quick request:

Add the below text to the end of the second paragraph of the "Galleri test" section, after "...43.1% positive predictive value for the detection of early-stage cancer.[1]":

Additionally, the test predicted the cancer signal origin with 97% accuracy.[1]

References

  1. ^ a b c "903O - A prospective study of a multi-cancer early detection blood test". ESMO Congress – OncologyPRO. 11 September 2022. Retrieved 26 July 2023.

Thank you! Mary Gaulke (talk) 18:05, 3 November 2023 (UTC)[reply]

The URL connected to this source doesn't appear to be functioning. This is what displays when following the link:

This page does not exist The requested page could not be found. Please use main navigation or search to find what you are looking for.

Oncology News Education Library Oncology in Practice Guidelines Meeting Resources Tumour Sites

Oh no. You didn't want to see this page…

We've re-designed and re-organised our website so a few pages may have moved. We've done our very, very best to set up highly-sophisticated page re-directs, but a few pages – like the one you were hoping to see – may have slipped through the net.

So I'm afraid there is not much I can do with this request.
Regards,  Spintendo  23:18, 3 November 2023 (UTC)[reply]

Edit request Nov 2023 v.2

[edit]

Hi again! The reference URL for the previous request went down after I posted it, so reposting with an updated link:

Add the below text to the end of the second paragraph of the "Galleri test" section, after "...43.1% positive predictive value for the detection of early-stage cancer.[1]":

Additionally, the test predicted the cancer signal origin with 97% accuracy.[1]

References

  1. ^ a b "903O - A prospective study of a multi-cancer early detection blood test". ESMO Congress – OncologyPRO. 11 September 2022. Retrieved 14 November 2023.

Thank you! Mary Gaulke (talk) 17:55, 14 November 2023 (UTC)[reply]

Approved The phrasing that I used for this was the following: "Results from PATHFINDER presented in September 2022 showed a 43.1% positive predictive value for the detection of early-stage cancer, with the test predicting the cancer signal origin with 97% accuracy in less than three months' time. as per the source. Regards,  Spintendo  22:07, 14 November 2023 (UTC)[reply]

April 2024 COI edit requests

[edit]

Hi! As noted above, I'm a COI editor for Grail. Requesting some updates to this article.

  • Add to end of second paragraph of "Galleri test" section:
Comprehensive prospective trial data published in The Lancet in October 2023 provided additional detail; of the 6,662 participants, 92 received a "cancer signal detected" result, and 35 were diagnosed with cancer. The median time between result and diagnostic resolution was 79 days.[1]
  • In "Galleri test" section, add after "The trial started on August 31, 2021, with primary completion date estimated at July 15, 2024, and study completion on February 28, 2026.":
SYMPLIFY, a separate NHS study led by the University of Oxford, evaluated the test's utility for symptomatic individuals.[2] Results published in The Lancet Oncology in June 2023 showed that the test had a positive predictive value of 75.5% and accurately predicted where a cancer signal came from in 85.2% of cases in which a cancer signal was detected in participants with cancer.[3]
  • Add to end of "Galleri test" section:
Grail partnered with the Whitman-Walker Institute and the Cancer Support Community on a study to assess Galleri's real-world feasibility in September 2023.[4] In November 2023, Grail initiated an investigational device exemption study to evaluate Galleri in up to 50,000 Medicare beneficiaries.[5] The study, called REACH (Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity), focuses particularly on historically underserved racial and ethnic minorities.[6]
  • Add a top-level "Recognition" section as follows:
Time listed Galleri among the 200 best inventions of 2022.[7] In 2023, Grail ranked #32 on the Fortune Change the World list of 59 companies addressing global challenges.[8]

References

  1. ^ Ashford, Molika (13 October 2023). "Grail Pathfinder Publication Offers Glimpse of Multi-Cancer Clinical Screening Impacts". Precision Medicine Online. Retrieved 7 April 2024.
  2. ^ Gregory, Andrew (2 June 2023). "Blood test for 50 types of cancer could speed up diagnosis, study suggests". The Guardian. Retrieved 8 April 2024.
  3. ^ Nicholson, Brian D.; Oke, Jason; Virdee, Pradeep S.; Harris, Dean A.; O'Doherty, Catherine; Park, John ES; Hamady, Zaed; Sehgal, Vinay; Millar, Andrew; Medley, Louise; Tonner, Sharon; Vargova, Monika; Engonidou, Lazarina; Riahi, Kaveh; Luan, Ying; Hiom, Sara; Kumar, Harpal; Nandani, Harit; Kurtzman, Kathryn N.; Yu, Ly-Mee; Freestone, Clare; Pearson, Sarah; Hobbs, FD Richard; Perera, Rafael; Middleton, Mark R. (2023). "Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): A large-scale, observational cohort study". The Lancet Oncology. 24 (7): 733–743. doi:10.1016/S1470-2045(23)00277-2. PMID 37352875.
  4. ^ Taylor, Nick Paul (1 September 2023). "Grail partners with LGBTQ+ group on study of cancer detection blood test". LabPulse.com. Retrieved 7 April 2024.
  5. ^ Young, Kerry Dooley (27 November 2023). "Grail Gets FDA OK for Study of Cancer Blood Test". Medscape. Retrieved 7 April 2024.
  6. ^ Anderson, Chris (22 November 2023). "Grail Launches Medicare Multi-Cancer Early Detection Study". Inside Precision Medicine. Retrieved 7 April 2024.
  7. ^ Withers, Ali (10 November 2022). "Grail Galleri Cancer Test: The 200 Best Inventions of 2022". Time. Retrieved 7 April 2024.
  8. ^ "2023 Change the World". Fortune. 2023. Retrieved 7 April 2024.

Thank you for your help! Mary Gaulke (talk) 18:49, 11 April 2024 (UTC)[reply]

Hi! Adding on two more requests for this article to reflect recent news.
  • Update the "name" parameter in the infobox to "GRAIL, Inc."[1]
  • At the end of "History", update
The European Commission (EC) has since approved Illumina's divestment plan for separating from Grail. Illumina has set a goal of finalizing the divestment terms by the end of the second quarter of 2024. In April 2024, the EC approved Illumina's plan, allowing Illumina to explore either a trade sale or a capital markets transaction (spin-off) to divest Grail. In May 2024, Illumina publicly filed a Form 10 registration statement with the U.S. SEC, a necessary step for a potential capital markets separation of Grail. If a capital markets transaction occurs, Illumina must capitalize Grail with around $1 billion to fund 2.5 years of operations per the EC's divestment plan.[2][3][4]
to
Illumina completed its spinoff of Grail in June 2024, and Grail began trading on the Nasdaq with ticker symbol GRAL. Illumina retained a 14.5% share of Grail.[5]

References

  1. ^ "Form S-1 Registration Statement". United States Securities and Exchange Commission. September 9, 2020. Retrieved July 11, 2024.
  2. ^ "Illumina's planned divestment of GRAIL approved by the European Commission". Illumina. 2024-05-06.
  3. ^ "Statement Regarding Illumina's Decision to Divest Grail". Federal Trade Commission. 2023-12-18.
  4. ^ "Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL". Illumina. 2019-02-01.
  5. ^ Hale, Conor (June 24, 2024). "Illumina parts ways with Grail, with divestiture complete". Fierce Biotech. Retrieved June 28, 2024.
Thank you! Mary Gaulke (talk) 18:37, 8 July 2024 (UTC)[reply]
Hi, thank you for your patience with this request. This is not a full review or decline yet, but note that I am concerned about the studies not passing WP:MEDRS, being in this context primary sources not contextualized by secondary sources. Rusalkii (talk) 04:50, 28 August 2024 (UTC)[reply]
 Not done I'm going to decline. None of these trials pass WP:MEDRS and in the light of more recent concerns about ethics and research fraud, would be extra inappropriate to use. Bon courage (talk) 07:12, 28 August 2024 (UTC)[reply]
Thanks, both, for your feedback! I see there have also been some substantial changes to the article since I posted these requests. I'll take all this into consideration and revise my requests. Thanks again. Mary Gaulke (talk) 15:50, 28 August 2024 (UTC)[reply]
Hi again! Apologies for double message – two clarifying questions I'm hoping are quick as I dig into revisions:
@Bon courage: Can you confirm if your reference to "ethics and research fraud" refers to this BMJ article cited in the current article? Couldn't find anything else on those topics and want to ensure I'm not missing anything.
@Rusalkii: The requests mention three studies but only directly cite one, in The Lancet Oncology. The other two mentions are cited to independent coverage in Precision Medicine Online, Medscape, and Inside Precision Medicine. Rereading WP:MEDRS, I believe The Lancet Oncology is the problematic source here, despite the publication, because it's primary. Please let me know if I'm missing something about the others that disqualifies them.
Thank you! Mary Gaulke (talk) 17:31, 28 August 2024 (UTC)[reply]
That's correct, though I am not at all confident that the secondary sources pass WP:MEDRS criteria for secondary sources for biomedical information either. (They might, I have not checked in depth and don't have a lot of expertise in this area, but it's a potential issue). Rusalkii (talk) 17:40, 28 August 2024 (UTC)[reply]
Yes, we're looking for secondary peer-reviewed sources for assertions (particularly bold ones) about biomedical science. None of the proffered sources meet that bar. Bon courage (talk) 17:54, 28 August 2024 (UTC)[reply]
Understood. Thank you both again! Mary Gaulke (talk) 19:16, 28 August 2024 (UTC)[reply]

Sept 2024 COI edit requests

[edit]

Hi again – I'm a COI editor for Grail, sharing edit requests revised based on recent changes to the article and feedback to my previous edit requests above:

  • Update the "name" parameter in the infobox to "GRAIL, Inc."[1]
  • Add to end of first paragraph of "Galleri test" section (using ref name[2]) in use in article):
The Galleri test detects circulating free DNA in a blood sample, using next-generation sequencing to identify DNA methylation, distinct patterns of which are associated with particular cancers, potentially allowing early detection of cancer and providing information of the origin of the cancer.[2][3][4]
This text was previously in the article and was deleted in this diff. I think it's valuable for the article to have a description of the mechanism of the test. I copy edited the text a bit for readability and added more sources, if helpful.
  • The text below (in longer form) was cut from the "Galleri test" section in this diff. I think it makes sense to restore some of it. I also made some cuts. Here's what I propose:
In 2018 data from Grail's first clinical trial for the Galleri test, the Circulating Cell-free Genome Atlas Study,[5] the test detected 87% of late-stage cancers and 38% of early-stage cancers.[6] The test does not diagnose cancer;[7] rather, it detects possible signs of cancer in order to help direct follow-up diagnostic testing.[8]
Galleri received breakthrough device designation from the U.S. Food and Drug Administration in May 2019.[9] In June 2021, the company began selling Galleri tests in the U.S.[10] The test is not approved by the FDA, but it is available by prescription under the agency's provision for laboratory developed tests.[11][12]
In November 2020, Grail announced a commercial partnership with the National Health Service to trial the Galleri test.[13]
Results from another trial, PATHFINDER, presented in September 2022 showed a 43.1% positive predictive value.[14][15][16]
  • Add to end of final paragraph of "Galleri test" additions in previous bullet:
Comprehensive prospective trial data published in The Lancet in October 2023 provided additional detail; of the 6,621 participants, 92 received a "cancer signal detected" result, and 35 were diagnosed with cancer.[17]
  • At the end of the "Galleri test" section, update
Grail is facing discontent and legal action from investors who suspect that its cancer testing claims misled them.[18]
to
In June 2024, news emerged that some Grail investors had initiated a class action lawsuit claiming the company exaggerated the Galleri test's potential impact.[18]
This lawsuit is also vaguely referred to in the lead, which strikes me as WP:UNDUE given the passing nature of the mention in the source (and the paucity of other major coverage).
  • Add to end of "Galleri test" section:
In November 2023, Grail initiated an investigational device exemption study, called REACH (Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity), to evaluate Galleri in up to 50,000 Medicare beneficiaries[19] with a focus on historically underserved racial and ethnic minorities.[20]
  • At the end of "History", update
The European Commission (EC) has since approved Illumina's divestment plan for separating from Grail. Illumina has set a goal of finalizing the divestment terms by the end of the second quarter of 2024. In April 2024, the EC approved Illumina's plan, allowing Illumina to explore either a trade sale or a capital markets transaction (spin-off) to divest Grail. In May 2024, Illumina publicly filed a Form 10 registration statement with the U.S. SEC, a necessary step for a potential capital markets separation of Grail. If a capital markets transaction occurs, Illumina must capitalize Grail with around $1 billion to fund 2.5 years of operations per the EC's divestment plan.[21][22][23]
to
Illumina completed its spinoff of Grail in June 2024, and Grail began trading on the Nasdaq with ticker symbol GRAL. Illumina retained a 14.5% share of Grail.[24]
  • Add a top-level "Recognition" section as follows:
Time listed Galleri among the 200 best inventions of 2022.[25] In 2023, Grail ranked #32 on the Fortune Change the World list of 59 companies addressing global challenges.[26]
Sources

  1. ^ "Form S-1 Registration Statement". United States Securities and Exchange Commission. September 9, 2020. Retrieved July 11, 2024.
  2. ^ a b Beer, Tomasz M. (1 November 2020). "Novel blood-based early cancer detection: diagnostics in development". The American Journal of Managed Care. 26 (14): S292–S299. doi:10.37765/ajmc.2020.88533. PMID 33200893.
  3. ^ Flynn, Hannah (16 September 2022). "Innovative blood test may detect cancers that are hard to diagnose". Medical News Today. Retrieved 28 August 2024.
  4. ^ "Illumina wants Grail back". Nature Biotechnology. 38 (11): 1227. 2020. doi:10.1038/s41587-020-0735-5. PMID 33144728.
  5. ^ Cisneros-Villanueva, M.; Hidalgo-Pérez, L.; Rios-Romero, M.; Cedro-Tanda, A.; Ruiz-Villavicencio, C. A.; Page, K.; Hastings, R.; Fernandez-Garcia, D.; Allsopp, R.; Fonseca-Montaño, M. A.; Jimenez-Morales, S.; Padilla-Palma, V.; Shaw, J. A.; Hidalgo-Miranda, A. (2022). "Cell-free DNA analysis in current cancer clinical trials: A review". British Journal of Cancer. 126 (3): 391–400. doi:10.1038/s41416-021-01696-0. PMC 8810765. PMID 35027672.
  6. ^ Mountfort, Katrina (25 June 2018). "The Quest for a Liquid Assay for Cancer Detection—The Circulating Cell-free Genome Atlas (CCGA) Study". touchONCOLOGY. Retrieved 30 August 2024.
  7. ^ "The Galleri Blood Test: What To Know". Health. 21 December 2022. Retrieved 26 July 2023.
  8. ^ Sample, Ian (11 September 2022). "Blood test spots multiple cancers without clear symptoms, study finds". The Guardian. Retrieved 26 July 2023.
  9. ^ Tirumalaraju, Divya (14 May 2019). "Grail gets FDA breakthrough designation for multi-cancer test". Medical Device Network. Retrieved 26 June 2023.
  10. ^ Nathan-Kazis, Josh (4 June 2021). "Grail Will Begin Selling Its Multi-Cancer Blood Test". Barron's. Retrieved 25 June 2023.
  11. ^ Kolata, Gina (10 June 2022). "Blood Tests That Detect Cancers Create Risks for Those Who Use Them". The New York Times. Retrieved 25 June 2023.
  12. ^ Sample, Ian (11 September 2022). "Blood test spots multiple cancers without clear symptoms, study finds". The Guardian. Retrieved 26 July 2023.
  13. ^ Gregory, Andy (27 November 2020). "NHS to trial 'game-changer' blood test for cancer in 2021". The Independent.
  14. ^ "903O - A prospective study of a multi-cancer early detection blood test". ESMO Congress – OncologyPRO. 11 September 2022. Retrieved 26 July 2023.
  15. ^ Kanski, Alison (12 September 2022). "ESMO Data Sharpens View of How Grail, Exact Sciences Multi-Cancer Early Detection Tests Perform". Precision Medicine Online. Retrieved 30 August 2024.
  16. ^ Nelson, Roxanne (11 September 2022). "Blood Test for Multiple Cancers: Many False Positives". Medscape. Retrieved 30 August 2024.
  17. ^ Lee, Richard; Robbins, Hilary A. (2023). "PATHFINDER: Another step on the uncharted path to multicancer screening". The Lancet. 402 (10409): 1213–1215. doi:10.1016/S0140-6736(23)02050-0. PMID 37805199.
  18. ^ a b McCartney M, Cohen D (7 August 2024). "Galleri promises to detect multiple cancers—but new evidence casts doubt on this much hyped blood test". BMJ (Investigation). doi:10.1136/bmj.q1706.
  19. ^ Young, Kerry Dooley (27 November 2023). "Grail Gets FDA OK for Study of Cancer Blood Test". Medscape. Retrieved 7 April 2024.
  20. ^ Anderson, Chris (22 November 2023). "Grail Launches Medicare Multi-Cancer Early Detection Study". Inside Precision Medicine. Retrieved 7 April 2024.
  21. ^ "Illumina's planned divestment of GRAIL approved by the European Commission". Illumina. 2024-05-06.
  22. ^ "Statement Regarding Illumina's Decision to Divest Grail". Federal Trade Commission. 2023-12-18.
  23. ^ "Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL". Illumina. 2019-02-01.
  24. ^ Hale, Conor (June 24, 2024). "Illumina parts ways with Grail, with divestiture complete". Fierce Biotech. Retrieved June 28, 2024.
  25. ^ Withers, Ali (10 November 2022). "Grail Galleri Cancer Test: The 200 Best Inventions of 2022". Time. Retrieved 7 April 2024.
  26. ^ "2023 Change the World". Fortune. 2023. Retrieved 7 April 2024.

Thank you for your feedback and help! Mary Gaulke (talk) 14:13, 3 September 2024 (UTC)[reply]

 Not done. Still loads of extraordinary WP:BMI sourced to primary sources. Asking for this kind of material to be included wastes editors' time and smacks of trying to use Wikipedia for promotion. This material is generally low-grade business information of no encyclopedic worth based on primary sources and churnalism. Bon courage (talk) 14:41, 3 September 2024 (UTC)[reply]

Hatchet job

[edit]

A fairly good article about the company and its major service (the Grail test) has been turned into a diatribe against the company and the test, in a short series of edits over the last month. When a Grail-affiliated person asked in the talk page for other editors to make some corrections, the same biased editor responded saying, "Asking for this kind of material to be included wastes editors' time and smacks of trying to use Wikipedia for promotion." It looks more to me like they asked to restore neutrality after User:Bon_courage promoted a negative point of view.

I have no connection with the company (except that on my doctor's advice, I took their test some years ago). But I was associated with the target of a recent (completely unrelated) hatchet job, so I am sensitive to the signs. I have little sympathy for biased writing or editing that removes large amounts of positive factual information to emphasize small and relatively inconsequential or unproven negative accusations.

Will some unaffiliated editors please read the article, compare it to how it looked in early August, look at the edit history, and make corrections as appropriate? Thank you. Gnuish (talk) 23:58, 6 September 2024 (UTC)[reply]

Wikipedia is not a brochure and "positive material" about medical outcomes needs to meet WP:MEDRS. The paid editor seemingly seems to want to brochure-ize this article by cramming in everything "positive" while carefully omitting everything negative about this company. (e.g.[1][2]). Wikipedia summarizes knowledge from the WP:BESTSOURCES to achieve neutrality. Your personal medical stories and lack of good faith are unwelcome; keep it up and expect to find yourself in trouble. Bon courage (talk) 05:56, 7 September 2024 (UTC); amended 15:27, 7 September 2024 (UTC)[reply]
I'm confused by this. Both of those stories have paragraphs dedicated to them in the current History section, which I'm not proposing be edited. Mary Gaulke (talk) 14:43, 7 September 2024 (UTC)[reply]
Apologies; I had not noticed they were there already (though it had to be added by other editors e.g.[3]). This material may be undue trivia in any case. Bon courage (talk) 15:28, 7 September 2024 (UTC)[reply]

Sept 2024 COI edit requests v.2

[edit]

Hi again! COI editor for Grail here, breaking down the requests below to exclude all biomedical information.

  • Update the "name" parameter in the infobox to "GRAIL, Inc."[1]
  • At the end of the "Galleri test" section, update
Grail is facing discontent and legal action from investors who suspect that its cancer testing claims misled them.[2]
to
In June 2024, news emerged that some Grail investors had initiated a class action lawsuit claiming the company exaggerated the Galleri test's potential impact.[2]
This lawsuit is also vaguely referred to in the lead, which strikes me as WP:UNDUE given the passing nature of the mention in the source (and the paucity of other major coverage).
  • At the end of "History", delete
The European Commission (EC) has since approved Illumina's divestment plan for separating from Grail. Illumina has set a goal of finalizing the divestment terms by the end of the second quarter of 2024. In April 2024, the EC approved Illumina's plan, allowing Illumina to explore either a trade sale or a capital markets transaction (spin-off) to divest Grail. In May 2024, Illumina publicly filed a Form 10 registration statement with the U.S. SEC, a necessary step for a potential capital markets separation of Grail. If a capital markets transaction occurs, Illumina must capitalize Grail with around $1 billion to fund 2.5 years of operations per the EC's divestment plan.[3][4][5]
Now that the spinoff is complete, this seems like more detail than is necessary on the transaction, especially cited to primary sources. Some of the tenses are also incorrect.
  • Add a top-level "Recognition" section as follows:
Time listed Galleri among the 200 best inventions of 2022.[6] In 2023, Grail ranked #32 on the Fortune Change the World list of 59 companies addressing global challenges.[7]
Sources

  1. ^ "Form S-1 Registration Statement". United States Securities and Exchange Commission. September 9, 2020. Retrieved July 11, 2024.
  2. ^ a b McCartney M, Cohen D (7 August 2024). "Galleri promises to detect multiple cancers—but new evidence casts doubt on this much hyped blood test". BMJ (Investigation). doi:10.1136/bmj.q1706.
  3. ^ "Illumina's planned divestment of GRAIL approved by the European Commission". Illumina. 2024-05-06.
  4. ^ "Statement Regarding Illumina's Decision to Divest Grail". Federal Trade Commission. 2023-12-18.
  5. ^ "Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL". Illumina. 2019-02-01.
  6. ^ Withers, Ali (10 November 2022). "Grail Galleri Cancer Test: The 200 Best Inventions of 2022". Time. Retrieved 7 April 2024.
  7. ^ "2023 Change the World". Fortune. 2023. Retrieved 7 April 2024.

I appreciate your time and feedback! Mary Gaulke (talk) 01:12, 20 September 2024 (UTC)[reply]

Regarding the various points here (numbering as per the order of the bullet points above):
1) It looks to me as though the top of the infobox already said "GRAIL, Inc." before you made this request, or am I missing something?
2) Declined. I'm not at all convinced that it would be advisable to re-word negative coverage of the subject of this article based on the opinion of an editor who is a paid PR operative working for the subject. The current coverage seems fine to me.
3) Please suggest an alternative version.
4) Declined. These are not notable events and their inclusion would be pure promotionalism. Being one of the top 200 inventions in a given year is a pretty low bar. The other event is just a mention in the kind of article which magazines of that nature regularly publish. It would be surprising if a company was never mentioned in such articles.
Regards, Axad12 (talk) 13:53, 16 October 2024 (UTC)[reply]
 Not done: Actually, upon further investigation I see that the edits above have already been turned down by user:Bon courage on the basis that Asking for this kind of material to be included wastes editors' time and smacks of trying to use Wikipedia for promotion. This material is generally low-grade business information of no encyclopedic worth based on primary sources and churnalism. I do not agree with the COI editor's apparent interpretation that that comment referred solely to the biomedical information. Clearly it did not.
Please do not make repeat requests to include promotional material that have already been declined. You are inching gradually closer towards a process being commenced that may lead to sanctions being placed on your account. Axad12 (talk) 14:02, 16 October 2024 (UTC)[reply]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Grail_(company)&oldid=1256176453"